Login to Your Account



Data 'selectin' probable ASCO winners; Glycomimetics AML biomarker distinct

By Randy Osborne
Staff Writer

Thursday, May 18, 2017

As abstracts rolled out for next month's American Society of Clinical Oncology (ASCO) meeting in Chicago, Glycomimetics Inc. whetted the appetite for more data from an ongoing phase II trial with E-selectin antagonist GMI-1271 in acute myeloid leukemia (AML).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription